[<sup>68</sup>Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [<sup>177</sup>Lu]DOTATOC PRRT: The “Theragnomics” Concept
Despite impressive results, almost 30% of NET do not respond to PRRT and no well-established criteria are suitable to predict response. Therefore, we assessed the predictive value of radiomics [<sup>68</sup>Ga]DOTATOC PET/CT images pre-PRRT in metastatic GEP NET. We retrospectively analy...
Main Authors: | Riccardo Laudicella, Albert Comelli, Virginia Liberini, Antonio Vento, Alessandro Stefano, Alessandro Spataro, Ludovica Crocè, Sara Baldari, Michelangelo Bambaci, Desiree Deandreis, Demetrio Arico’, Massimo Ippolito, Michele Gaeta, Pierpaolo Alongi, Fabio Minutoli, Irene A. Burger, Sergio Baldari |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/4/984 |
Similar Items
-
<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans
by: Licia Uccelli, et al.
Published: (2021-09-01) -
Relevance of Volumetric Parameters Applied to [<sup>68</sup>Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT
by: Luca Urso, et al.
Published: (2023-02-01) -
Diagnostic Impact of Dual-Time PET/CT with <sup>68</sup>Gallium-PSMA in Prostate Cancer and <sup>68</sup>Gallium-DOTATOC in Neuroendocrine Tumors
by: Damiano Librizzi, et al.
Published: (2023-03-01) -
Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01) -
The Dependence of Renal <sup>68</sup>Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu[Lu]-DOTATOC
by: Falk Gühne, et al.
Published: (2021-07-01)